Motilal Oswal is bullish on Lupin has recommended buy rating on the stock with a target price of Rs 1850 in its research report dated February 09, 2017.
Motilal Oswal's research report on Lupin
Glumetza/Fortamet continue to be the key contributors to profits. Glumetza may continue to see limited competition in near term. Along with this, strong launch pipeline and ramp-up of Methergen sales can help drive US business over near term. Maintain Buy with TP of INR 1,850 @ 22x 1HFY19E PER (v/s INR 1,825 @ 22x 1H FY19E PER). We raise FY17E/18E EPS by 2-3% as we build impact of limited competition in Glumetza.
For all recommendations, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.